Our senior management team’s leadership and vision are critical to the company’s operational efficiency and growth, positioning us well to continue bringing important therapeutics to patients in need.
President and Chief Executive Officer
Scott Myers is a proven executive who brings nearly three decades of global pharmaceutical and medical technology experience who has been...
Scott Myers is a proven executive who brings nearly three decades of global pharmaceutical and medical technology experience who has been President and Chief Executive Officer of AMAG since April 2020. Mr. Myers most recently served as Chairman and Chief Executive Officer of Rainier Therapeutics, a clinical-stage biotechnology company focused on metastatic bladder cancer. Prior to joining Rainier, Mr. Myers served as Chief Executive Officer, President and Director of Cascadian Therapeutics Inc. Mr. Myers also served as Chief Executive Officer of Aerocrine AB, a medical device company from 2011 to 2015. While at the helm of these companies, Mr. Myers drove transformation that maximized growth and delivered significant long-term value. Mr. Myers is currently an Independent Director for Selecta Biosciences where he serves as the Chair of the Compensation and Benefits Committee, as well as a member of the Nominating and Governance Committee. Mr. Myers also serves as an Independent Director for Harpoon Therapeutics, a clinical stage biotechnology company where he serves on the Audit Committee. Mr. Myers began his career in management consulting and then moved into the pharmaceutical industry through senior leadership roles at Johnson & Johnson, DOV Pharmaceuticals and UCB. Mr. Myers holds a Bachelor of Arts in Biology from Northwestern University in Evanston, Illinois, and a Master of Business Administration from The University of Chicago Graduate School of Business (Booth) in Chicago, Illinois.
Executive Vice President, Chief Operating Officer
Tony Casciano serves as AMAG’s Chief Operating Officer, bringing over 20 years of commercial experience within the pharmaceutical...
Tony Casciano serves as AMAG’s Chief Operating Officer, bringing over 20 years of commercial experience within the pharmaceutical industry. He joined AMAG in September 2016 and has since held positions of increasing responsibility in the Company. Prior to AMAG, Mr. Casciano served as the Head of Marketing for General Medicines at Sanofi. During his 16 year career at Sanofi, he held multiple commercial leadership roles across a broad range of departments and therapeutic areas. He was also responsible for building and leading top-performing cross-functional commercial teams to achieve aggressive goals for more than a dozen specialty brands. Mr. Casciano holds a Bachelor of Science degree in business administration from Bridgewater State College.
Interim Chief Financial Officer
Brian Piekos serves as AMAG’s interim Chief Financial Officer. He joined AMAG in 2015 and has held a number of senior management positions...
Brian Piekos serves as AMAG’s interim Chief Financial Officer. He joined AMAG in 2015 and has held a number of senior management positions with the Company. In his most recent role as Senior Vice President of Finance, Mr. Piekos has provided oversight of AMAG’s financial planning and reporting, tax, treasury and strategic sourcing processes. He has more than 20 years of corporate finance experience including strategic planning, financial reporting and capital market activities. Prior to joining AMAG, he held positions of increasing responsibility at Cubist Pharmaceuticals. Mr. Piekos began his career in investment banking having served as Vice President at Leerink Partners and as an analyst at Needham & Company. Mr. Piekos graduated from Ithaca College with B.A. in Biochemistry. He also received an M.S. in Molecular Biology from the University of Massachusetts Medical School and an MBA from University of Rochester’s Simon Business School.
Senior Vice President, Chief Human Resources Officer and Head of Corporate Engagement
Kelly Schick serves as AMAG’s Senior Vice President, Chief Human Resources Officer and Head of Corporate Engagement. She joined AMAG in...
Kelly Schick serves as AMAG’s Senior Vice President, Chief Human Resources Officer and Head of Corporate Engagement. She joined AMAG in September 2016 and has more than 15 years of human resource experience in the pharmaceutical industry. Prior to AMAG, Ms. Schick served as Head of Global Talent for Bristol-Myers Squibb (BMS) where she had responsibility for global talent management, talent acquisition, learning and development, organization effectiveness and diversity and inclusion for the company's global manufacturing division. Before joining BMS in 2011, Ms. Schick held a series of HR business partner roles of increasing responsibility supporting the research and development organization for Merck and Company, Inc. Ms. Schick holds a Bachelor of Arts in psychology from Boston University and a Master of Arts in human resources and labor relations from the Curtis L. Carlson School of Management at the University of Minnesota.
Joseph D. Vittiglio
Executive Vice President, General Counsel, Chief Business Officer & Corporate Secretary
Joseph Vittiglio serves as AMAG’s Executive Vice President, General Counsel, Chief Business Officer and Corporate Secretary. Before...
Joseph Vittiglio serves as AMAG’s Executive Vice President, General Counsel, Chief Business Officer and Corporate Secretary. Before joining AMAG, he served as Vice President of Legal Affairs and a member of the management committee at Flexion Therapeutics, Inc. Prior to that, Mr. Vittiglio was the General Counsel of AVEO Pharmaceuticals and the Director of Legal Affairs at Oscient Pharmaceuticals Corporation. He began his legal career as an Associate Attorney at Gaffin & Krattenmaker, P.C., before joining Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC as a senior attorney in 1998. Mr. Vittiglio holds a Bachelor of Science degree in international relations from Tufts University and a Juris Doctor from Northeastern University School of Law.